| Document |
Document Title |
|
WO/2023/236982A1 |
The present invention relates to the technical field of organic electroluminescent materials, and in particular to a phenanthridine derivative and the use thereof. The phenanthridine derivative having a structural formula shown in formul...
|
|
WO/2023/239768A1 |
The present application provides tricyclic triazolo compounds I that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
|
|
WO/2023/239629A1 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof that are useful as modulators of targeted ubiquitination. The compounds disclosed herein bind to and degrade one or more cyclin dependent kinases 2 (CDK2).
|
|
WO/2023/238769A1 |
An organic electroluminescent element (1) has an anode (3), a cathode (4), and a light-emitting layer (5) provided between the anode (3) and the cathode (4). The light-emitting layer (5) contains a compound M3 represented by general form...
|
|
WO/2023/237050A1 |
Antibody-drug conjugate compounds comprising a linker and methods of using such compounds are provided.
|
|
WO/2023/239729A1 |
The present disclosure is directed to compounds of Formula (I): wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable s...
|
|
WO/2023/238629A1 |
The present disclosure provides an organic compound characterized by being represented by general formula [1]. In general formula [1], Ar1 and Ar2 are each independently selected from among an aryl group and a heterocyclic group. Ar1 and...
|
|
WO/2023/232145A1 |
Disclosed in the present invention are a small molecule of homocamptothecins and the use thereof. Specifically disclosed in the present invention are a small molecule of homocamptothecins as shown in formula (I) or a pharmaceutically acc...
|
|
WO/2023/231795A1 |
The present invention relates to the technical field of organic electroluminescent materials, and particularly relates to a heterocyclic compound and the use thereof. The structural formula of the compound is as shown in formula (I). The...
|
|
WO/2023/233033A1 |
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as PAR-2 inhibitors, which renders these compounds highly advantageous for use...
|
|
WO/2023/232025A1 |
The present invention relates to tricyclic compounds of formula (I), pharmaceutical compositions comprising same, preparation methods therefor, and uses thereof, wherein each variable is as defined in the description.
|
|
WO/2023/234749A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/233130A1 |
The present invention relates to compounds of formula I shown below: wherein R1, X2, X3, X4, X5, X6, X7, X8 and X9 are each as defined in the application. The present invention also relates to processes for the preparation of these compo...
|
|
WO/2023/227006A1 |
The present invention relates to the technical field of drug synthesis, and provides a dideuterated camptothecin derivative as shown in general formula Q and a preparation method therefor and in vitro biological activity and use thereof....
|
|
WO/2023/229375A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, exhibiting a diacylglycerol kinase inhibitor activity, a pharmaceutical composition comprising same as an active ingredient, and use thereof.
|
|
WO/2023/227698A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
|
WO/2023/230059A1 |
The disclosure includes compounds of Formula (1) wherein each of R, R1, R2, R2A, R3, R4, R5, R6, R, L1, L2, L3, L4, L5, L6, Q1, Q2, Q3, m, n, r, s, and t, are defined herein. Also disclosed is a method for treating a neoplastic disease, ...
|
|
WO/2023/224128A1 |
The present invention relates to a pharmaceutical composition for treating or preventing fibrosis, the pharmaceutical composition containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/225588A2 |
Aspects of this invention are related to novel compounds of Formula I and compositions thereof that are inhibitors of glycogen synthase kinase 3 beta (GSK3[3). Some aspects of the invention relate to novel compounds and compositions havi...
|
|
WO/2023/222137A1 |
Provided are a novel tetrahydroisoquinoline compound, a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof. Specifically, provided are a nitrogen-containing heterocyclic compound as repr...
|
|
WO/2023/222084A1 |
Disclosed in the present invention are a benzimidazole or azabenzimidazole compound, a preparation method therefor and a use thereof. The benzimidazole or azabenzimidazole compound has a structure shown in formula (I). A use of the compo...
|
|
WO/2023/222589A1 |
Compounds of the formula (I), (I), wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2023/224413A1 |
The present specification provides a heterocyclic compound, an organic light-emitting element comprising same, and a composition for an organic layer of an organic light-emitting element.
|
|
WO/2023/222850A1 |
The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
|
|
WO/2023/221797A1 |
The present invention relates to a heterocyclic compound, a pharmaceutical composition comprising same, and a preparation method for the heterocyclic compound, and further relates to a use of the compound in the preparation of a drug for...
|
|
WO/2023/225586A2 |
Aspects of this invention are related to novel compounds of Formula I and compositions thereof that are inhibitors of glycogen synthase kinase 3 beta (GSK3β). Some aspects of the invention relate to novel compounds and compositions havi...
|
|
WO/2023/221022A1 |
Disclosed in the present invention are intermediate I and intermediate II which have structural formulas as represented by formula (I) and formula (II), respectively, and can be used for preparing galantamine, and a preparation method th...
|
|
WO/2023/217230A1 |
The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
|
|
WO/2023/216956A1 |
The present invention relates to a camptothecin compound with anti-tumor activity, a preparation method therefor and use thereof. In particular, the present invention relates to a compound of the following formula or a pharmaceutically a...
|
|
WO/2023/220439A1 |
Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
|
WO/2023/220433A1 |
Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
|
WO/2023/218245A1 |
The present invention relates to heteroaryl derivative compounds and a pharmaceutical composition comprising thereof. Specifically, the present invention relates to heteroaryl derivative compounds having RAF inhibitory activity.
|
|
WO/2023/217227A1 |
The present disclosure relates to a ligand-drug conjugate of a novel structure or a pharmaceutically acceptable salt thereof. Specifically, the present disclosure provides a ligand-drug conjugate having a structural general formula repre...
|
|
WO/2023/217064A1 |
The present invention belongs to the field of pharmaceutical chemistry, and relates to a camptothecin derivative, an antibody-drug conjugate and pharmaceutical composition based on same, and the use thereof. The derivative has a structur...
|
|
WO/2023/217906A1 |
The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventin...
|
|
WO/2023/220541A1 |
Tetrahydropyrido[3,4-d]pyrimidine compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly hum...
|
|
WO/2023/220435A1 |
Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
|
WO/2023/214651A1 |
The present invention relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting element comprising same.
|
|
WO/2023/214650A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/215238A1 |
Described herein are new 8,9-dialoxy-7-azaindenoisoquinoline compounds (I), processes for their preparation, and methods of their use in the treatment of diseases responsive to inhibition of topoisomerase 1 and/or binding to the c-MYC G-...
|
|
WO/2023/214836A1 |
The present invention relates to a novel berberine analogue CD1-410. It has been identified that the novel berberine analogue promotes the activity of mitophagy, and thus can reduce mitochondria with a damaged structure and/or function. ...
|
|
WO/2023/207991A1 |
Disclosed in the present invention are a fused quinazoline compound and the use thereof. Specifically, the present invention relates to a compound as represented by formula (IV) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/212219A1 |
Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
|
|
WO/2023/206274A1 |
The present disclosure provides an organic electroluminescent diode and a display panel, belonging to the technical field of display. The organic electroluminescent diode comprises an anode, a luminescent layer, a hole blocking layer, an...
|
|
WO/2023/207773A1 |
Provided are conjugates of novel camptothecin analogs with a cell binding molecule of formula (I). It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of application the c...
|
|
WO/2023/212240A1 |
The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods o...
|
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
|
WO/2023/210192A1 |
This compound, represented by a general formula, is useful in a light-emitting device. Ar1 is a benzene ring, a naphthalene ring, a phenanthrene ring, or the like; D is a 5H-benzofuro[3,2-c]carbazol-5-yl group, or the like; A is a cyano ...
|
|
WO/2023/211990A1 |
Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-ga...
|
|
WO/2023/201421A1 |
The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
